Researchers from Biorchestra Ltd. presented preclinical data for BMD-001, a novel nanoparticle-formulated antisense oligonucleotide (ASO) being developed for the treatment of Parkinson’s disease (PD). miR-485-3p has been previously identified as a pathway and therapeutic target in neuroinflammatory disease, and the potential relevance of this target in PD was further confirmed through RNA-Seq and analysis of expression levels in animal models and patients with PD.
Researchers from Attralus Inc. reported preclinical data for AT-04, a novel peptibody designed to bind neuropathologic fibrillar aggregates in the brains of patients with Alzheimer’s disease (AD).
The common pathological pathway in progressive chronic kidney disease (CKD) is tissue fibrosis and chemokine receptor type 4 (CXCR4) plays a key role in the development of fibrosis.
Abbvie Inc. recently disclosed the discovery and structure of the anti-tumor necrosis factor (TNF) glucocorticoid receptor modulator (GRM) immunology antibody-drug conjugate (iADC) ABBV-154. The drug is in phase II clinical development as a subcutaneous treatment for rheumatoid arthritis and polymyalgia rheumatica, and as a subcutaneous or intravenous treatment for active Crohn’s disease.
Murine models are primarily used in Alzheimer’s disease (AD) research, but differences between rodents and primates may prevent a true understanding of the mechanisms of the disease.
To date, only one drug has been approved for the treatment of itch (persistent pruritus) and it only targets a small portion of the patient population. Researchers from Mallinckrodt plc have unveiled gastrin-releasing peptide receptor (GRPR) as an itch-specific receptor for nonhistaminergic itch.
Researchers from the University of Arizona presented the discovery of first-in-class dual-specificity tyrosine phosphorylation-regulated kinase 1A/B (DYRK1A/B) proteolysis targeting chimeras (PROTACs) as potential Alzheimer’s disease (AD) therapeutic candidates.
Protein-tyrosine phosphatase SHP-1 is a negative regulator of immune cell function and is broadly expressed in the hematopoietic compartment. Due to its role in immune cell signaling, SHP-1 may be explored as a target for tumor immunotherapy.
Immunoglobulin A (IgA) nephropathy is the most prevalent glomerulonephritis worldwide that does not have a specific treatment. Its pathogenesis is complex and not well understood, but there is increasing evidence that the lectin-driven complement activation may be behind it. Mannose-binding lectin serine protease 2 (MASP-2) has been studied as a therapeutic target in the treatment of IgA nephropathy, as it is one of the main lectin pathway activators.
RSS
